GSK Forms China R&D Unit To Develop TCM Meeting Clinical-Trial Tests
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline said it plans to launch a research-and-development subsidiary in China to study traditional Chinese medicine to see if it can survive evidence-based testing.